Publications

Export 72 results:
Auteur Title [ Type(Desc)] Année
Filtres: Auteur is Pedro Rosa-Neto  [Enlever les filtres]
Journal Article
Gauthier S, Rosa-Neto P, Kass JS.  2016.  Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients.. Continuum (Minneap Minn). 22(2 Dementia):615-8.
Bailey JJ, Kaiser L, Lindner S, Wüst M, Thiel A, Soucy J-P, Rosa-Neto P, Scott PJH, Unterrainer M, Kaplan DR et al..  2019.  First-in-Human Brain Imaging of [F]TRACK, a PET tracer for Tropomyosin Receptor Kinases.. ACS Chem Neurosci. 10(6):2697-2702.
Henriques ADallanora, Benedet ALessa, Camargos EFrancisco, Rosa-Neto P, Nóbrega OToledo.  2018.  Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.. Exp Gerontol.
Gauthier S, Leuzy A, Rosa-Neto P.  2014.  How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease? Neurodegener Dis. 13(2-3):197-9.
Bernard-Gauthier V, Mossine AV, Mahringer A, Aliaga A, Bailey JJ, Shao X, Stauff J, Arteaga J, Sherman P, Grand'Maison M et al..  2018.  Identification of [F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging.. J Med Chem. 61(4):1737-1743.
Mathotaarachchi S, Pascoal TA, Shin M, Benedet AL, Kang MSu, Beaudry T, Fonov VS, Gauthier S, Rosa-Neto P.  2017.  Identifying incipient dementia individuals using machine learning and amyloid imaging.. Neurobiol Aging. 59:80-90.
Leuzy A, Zimmer ERigon, Bhat V, Rosa-Neto P, Gauthier S.  2014.  Imaging biomarkers for amyloid: a new generation of probes and what lies ahead.. Int Psychogeriatr. 26(5):703-7.
Zimmer ER, Parent MJ, Leuzy A, Aliaga A, Aliaga A, Moquin L, Schirrmacher ES, Soucy J-P, Skelin I, Gratton A et al..  2015.  Imaging in vivo glutamate fluctuations with [(11)C]ABP688: a GLT-1 challenge with ceftriaxone.. J Cereb Blood Flow Metab. 35(7):1169-74.
Leuzy A, Zimmer ERigon, Dubois J, Pruessner J, Cooperman C, Soucy J-P, Kostikov A, Schirmaccher E, Désautels R, Gauthier S et al..  2015.  In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD.. Brain Struct Funct.
Pascoal TA, Shin M, Kang MSu, Chamoun M, Chartrand D, Mathotaarachchi S, Bennacef I, Therriault J, Ng KPin, Hopewell R et al..  2018.  In vivo quantification of neurofibrillary tangles with [F]MK-6240.. Alzheimers Res Ther. 10(1):74.
Zimmer ERigon, Leuzy A, Bhat V, Gauthier S, Rosa-Neto P.  2014.  In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals.. Transl Neurodegener. 3(1):6.
Meyer P-F, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Maignan M-É, Savard M, Rosa-Neto P, Poirier J, Etienne P, Breitner JCS.  2019.  INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.. Neurology. 92(18):e2070-e2080.
Bernard-Gauthier V, Bailey JJ, Mossine AV, Lindner S, Vomacka L, Aliaga A, Shao X, Quesada CA, Sherman P, Mahringer A et al..  2017.  A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human.. J Med Chem. 60(16):6897-6910.
Milella MS, Marengo L, Larcher K, Fotros A, Dagher A, Rosa-Neto P, Benkelfat C, Leyton M.  2014.  Limbic system mGluR5 availability in cocaine dependent subjects: a high-resolution PET [(11)C]ABP688 study.. Neuroimage. 98:195-202.
Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER et al..  2019.  Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.. Alzheimers Dement. 15(6):742-753.
DuBois JM, Rousset OG, Guiot M-C, Hall JA, Reader AJ, Soucy J-P, Rosa-Neto P, Kobayashi E.  2016.  Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging.. Cereb Cortex.
Zimmer ER, Parent MJ, A Cuello C, Gauthier S, Rosa-Neto P.  2014.  MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research.. Trends Neurosci. 37(11):629-41.
Ng KPin, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MSu, Shin M, Guiot M-C, Guo Q, Harada R, Comley RA et al..  2017.  Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain.. Alzheimers Res Ther. 9(1):25.
Parent MJ, Zimmer ER, Shin M, Kang MSu, Fonov VS, Mathieu A, Aliaga A, Kostikov A, Carmo SDo, Dea D et al..  2017.  Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.. J Neurosci. 37(50):12263-12271.
Ng KPin, Pascoal TA, Mathotaarachchi S, Chung C-O, Benedet AL, Shin M, Kang MSu, Li X, Ba M, Kandiah N et al..  2017.  Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 88(19):1814-1821.
Meyer P-F, Labonte A, Rosa-Neto P, Poirier J, Breitner JCS.  2019.  No apparent effect of naproxen on CSF markers of innate immune activation.. Ann Clin Transl Neurol. 6(6):1127-1133.
Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C et al..  2019.  Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease.. Nat Commun. 10(1):4227.
Lafaille-Magnan M-E, Poirier J, Etienne P, Tremblay-Mercier J, Frenette J, Rosa-Neto P, Breitner JCS.  2017.  Odor identification as a biomarker of preclinical AD in older adults at risk.. Neurology. 89(4):327-335.
Gauthier S, Herrmann N, Rosa-Neto P.  2018.  Optimal use of cholinergic drugs in Alzheimer's disease.. Brain.
Cyr M, Parent MJ, Mechawar N, Rosa-Neto P, Soucy J-P, Aliaga A, Kostikov A, Maclaren DAA, Clark SD, Bedard M-A.  2014.  PET imaging with [¹⁸F]fluoroethoxybenzovesamicol ([¹⁸F]FEOBV) following selective lesion of cholinergic pedunculopontine tegmental neurons in rat.. Nucl Med Biol. 41(1):96-101.

Pages